LAUSR

Psoriasis (PSO), an immune‐mediated chronic inflammatory skin disease, has seriously affected the quality of patients' life. It is urgent to find effective medicines with lower costs and less side effects. Baicalin (HQG) is the main bioactive substance from Scutellaria baicalensis with effects of anti‐inflammation and immunoregulation. Herein, we explored the effect of oral HQG treating PSO and its potential mechanism. Firstly, network pharmacology was used to predict that HQG may act on Estrogen, TNF‐alpha (tumor necrosis factor, TNF), interleukin‐17 (IL‐17) signaling pathways and Th17 cell differentiation, especially the key targets including TNF, Proto‐oncogene tyrosine‐protein kinase Src, Peroxisome proliferator‐activated receptor gamma and Matrix metalloproteinase‐9. Imiquimod (IMQ)‐induced mice were then used to study the effects of HQG treating PSO. HQG could significantly ameliorate the skin lesions, decrease the level of inflammatory factors and inhibit Th1/Th17 cell differentiation in IMQ‐induced mice. Finally, transcriptome analysis of skin lesions integrated with the prediction of network pharmacology further demonstrated that the potential mechanism may be associated with suppressing Wnt signaling pathway and inhibiting Th17/IL‐17 axis by activating PPARγ. In conclusion, this study suggested that HQG may be a promising agent for further studies in the search for therapeutic strategies to treat PSO in the future.